OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+16.56%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$126M
AUM Growth
+$126M
(+21%)
Cap. Flow
+$6.07M
Cap. Flow
% of AUM
4.81%
Top 10 Holdings %
Top 10 Hldgs %
42.55%
Holding
65
New
10
Increased
31
Reduced
2
Closed
1
Top Buys
| 1 |
Qiagen
QGEN
|
$3.24M |
| 2 |
Axsome Therapeutics
AXSM
|
$1.04M |
| 3 |
Heron Therapeutics
HRTX
|
$476K |
| 4 |
PGNX
Progenics Pharmaceuticals Inc
PGNX
|
$411K |
| 5 |
Akebia Therapeutics
AKBA
|
$387K |
Top Sells
| 1 |
QGENF
QIAGEN NV
QGENF
|
$3.13M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$760K |
| 3 |
Direxion Daily S&P Biotech Bull 3X Shares
LABU
|
$266K |
Sector Composition
| 1 | Healthcare | 79.39% |
| 2 | Real Estate | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $9.01M | 6.69% | 130,000 | – | – |
|
2
iShares Biotechnology ETF
IBB
$5.6B
| $7.33M | 5.44% | 25,000 | – | – |
|
3
Merck
MRK
$210B
| $5.32M | 3.95% | 83,700 | – | – |
|
4
Alkermes
ALKS
$4.78B
| $4.93M | 3.66% | 84,190 +1,894 | +2% | +$111K |
|
5
Bristol-Myers Squibb
BMY
$96B
| $4.89M | 3.63% | 90,000 | – | – |
|
6
Incyte
INCY
$16.5B
| $4.71M | 3.5% | 35,240 +209 | +0.6% | +$27.9K |
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.62M | 3.43% | 90,121 +1,337 | +2% | +$68.5K |
|
8
Nektar Therapeutics
NKTR
$568M
| $4.37M | 3.25% | 186,287 +1,959 | +1% | +$46K |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.37M | 3.24% | 69,512 +1,202 | +2% | +$75.6K |
|
10
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $4.1M | 3.04% | 85,000 | – | – |
|
11
Pfizer
PFE
$141B
| $3.84M | 2.85% | 112,300 | – | – |
|
12
AstraZeneca
AZN
$248B
| $3.74M | 2.77% | 120,000 | – | – |
|
13
Vertex Pharmaceuticals
VRTX
$100B
| $3.72M | 2.76% | 34,006 +649 | +2% | +$71K |
|
|
CELG
14
DELISTED
Celgene Corp
CELG
| $3.51M | 2.6% | 28,197 +911 | +3% | +$113K |
|
15
Mettler-Toledo International
MTD
$26.8B
| $3.44M | 2.55% | 7,188 | – | – |
|
16
Agios Pharmaceuticals
AGIO
$2.19B
| $3.35M | 2.49% | 57,410 +1,886 | +3% | +$110K |
|
17
Illumina
ILMN
$15.8B
| $3.32M | 2.46% | 19,432 +465 | +2% | +$79.4K |
|
|
18
Qiagen
QGEN
$10.1B
| $3.24M | 2.4% | +111,763 | New | +$3.24M |
|
19
Amgen
AMGN
$155B
| $3.18M | 2.36% | 19,401 +658 | +4% | +$108K |
|
20
Ionis Pharmaceuticals
IONS
$6.79B
| $3.17M | 2.35% | 78,900 +1,350 | +2% | +$54.3K |
|
21
Biogen
BIIB
$19.4B
| $3.12M | 2.31% | 11,404 +532 | +5% | +$145K |
|
22
Regeneron Pharmaceuticals
REGN
$61.5B
| $3.11M | 2.31% | 8,035 +351 | +5% | +$136K |
|
23
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.89M | 2.14% | 32,911 +1,332 | +4% | +$117K |
|
24
GSK
GSK
$79.9B
| $2.53M | 1.88% | 60,000 | – | – |
|
25
Pacira BioSciences
PCRX
$1.2B
| $2.28M | 1.69% | 50,000 | – | – |
|